Form 4: Aurinia Director's Tax-Related Stock Sale

Aurinia Pharmaceuticals Director Jeffrey Allen Bailey disposed of 2,716 common shares to cover tax obligations related to restricted stock unit vesting.

Summary

• Jeffrey Allen Bailey, a Director of Aurinia Pharmaceuticals Inc. (AUPH), reported a transaction on November 21, 2025.
• The transaction involved the disposition of 2,716 common shares at a price of $15.68 per share.
• These shares were withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.
• Following this transaction, Jeffrey Allen Bailey beneficially owns 22,775 common shares directly.
• The filing indicates this transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The transaction is a routine tax-related disposition of shares upon RSU vesting, not indicative of positive or negative sentiment towards the company's future performance or the director's confidence.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction filing (Form 4) reporting a director's disposition of shares for tax purposes, which is a common occurrence in the pharmaceutical industry and generally not indicative of broader industry trends or competitive positioning.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine tax-related transaction and not a discretionary sale or purchase.

Key Dates

Keywords

Aurinia Pharmaceuticals, AUPH, Form 4, Insider Transaction, Director, Stock Sale, Tax Withholding, Restricted Stock Units